BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The revolution in the treatment of CML patients that has resulted from the specific and potent targeting of the BCR-ABL kinase with STI571/Gleevec/Imatinib Mesylate [8-10] serves as an important reminder of the advances that can come from an understanding of the molecular basis of disease.